Belinostat como tratamiento del linfoma de células T periférico recidivante: Revisión Sistemática

Abstract

Title: Belinostat as Treatment for Relapsed Peripheral T-Cell Lymphoma: A Systematic Review Objective: This study aims to determine the therapeutic utility of Belinostat in relapsed peripheral T-cell lymphoma. Methodology: A systematic review was conducted, including clinical trials and case reports, in which a search was performed in databases such as PubMed, Scopus, and Web of Science, reporting on drug tolerability and progression-free survival. Results: Four studies that met the eligibility criteria were considered. The selected articles included 303 patients, and it was found that Belinostat, a histone deacetylase inhibitor, has a 25% response rate. Discussion: Studies on patients with relapsed/refractory peripheral T-cell lymphoma treated with Belinostat monotherapy showed moderate efficacy. The probability of maintaining a response was 57.7% at six months, 48.8% at one year, and 32.6% at two years, confirming that this medication has a favorable safety profile. However, most patients experienced hematological complications, with a generally low incidence of thrombocytopenia, suggesting that combining Belinostat with cytotoxic therapies is safe. Conclusions: Clinical data from a patient with refractory peripheral T-cell lymphoma demonstrated a complete remission lasting 39 months with Belinostat treatment, highlighting its efficacy in specific cases. On the other hand, the hematological toxicity associated with the drug appears to be manageable, suggesting a favorable safety profile